Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.67+0.15 (+0.49%)
Close on Nov 2, 2026Market cap $174.81BP/E 40.4Yield 5.61%
Pfizer Lorbrena / Lorviqua (lorlatinib by Quarter
Lorbrena / Lorviqua (lorlatinib — ALK+ NSCLC) — U.S. reported YoY (%) (%)
Pfizer Lorbrena / Lorviqua (lorlatinib: 33.0% in Q2 2026, down 10.0 pts from a year earlier.
Latest, Q2 2026
33.0%
Period ended Jun 28, 2026
Change on a year earlier
-10.0 pts
43.0% in Q2 2025
History
24 quarters
Since Q3 2020
Sources
24
Documents cited below
Where the Q2 2026 figure comes from
“|| Lorbrena | 354 | 251 | 41% | 37% | 133 | 100 | 33% | 221 | 151 | 46% | 40%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Reported in Form 8-K Revenue Tables.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Pfizer Lorbrena / Lorviqua (lorlatinib (%), quarterly Q3 2020–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/lorbrena-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.